This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barone, J. A.
Right arrow Articles by Jessen, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barone, J. A.
Right arrow Articles by Jessen, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1998, p. 1862-1865, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Enhanced Bioavailability of Itraconazole in Hydroxypropylbeta -Cyclodextrin Solution versus Capsules in Healthy Volunteers

Joseph A. Barone,1,* Bruce L. Moskovitz,2 Joseph Guarnieri,2 Alan E. Hassell,2 John L. Colaizzi,1 Robert H. Bierman,1 and Lois Jessen1

Rutgers---The State University of New Jersey, Piscataway,1 and Janssen Research Foundation, Titusville,2 New Jersey

Received 7 July 1997/Returned for modification 24 December 1997/Accepted 6 April 1998

The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two capsule formulations were evaluated in a crossover study of 30 male volunteers. The two capsule formulations were bioequivalent. The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule. However, the maximum concentrations of the drug in plasma (Cmax), the times to Cmax, and the terminal half-lives were comparable for all three formulations. These data indicate that the bioavailabilities of itraconazole and hydroxyitraconazole are enhanced when administered as an oral solution instead of capsules.

* Corresponding author. Mailing address: College of Pharmacy, Rutgers---The State University of New Jersey, William Levine Hall, Frelinghuysen Rd., Piscataway, NJ 08855-0789. Phone: (732) 445-3285. Fax: (732) 445-2533. E-mail: jbarone{at}rci.rutgers.edu.

Antimicrobial Agents and Chemotherapy, July 1998, p. 1862-1865, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Andes, D., Pascual, A., Marchetti, O. (2009). Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrob. Agents Chemother. 53: 24-34 [Full Text]  
  • Abdel-Rahman, S. M., Jacobs, R. F., Massarella, J., Kauffman, R. E., Bradley, J. S., Kimko, H. C., Kearns, G. L., Shalayda, K., Curtin, C., Maldonado, S. D., Blumer, J. L. (2007). Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-{beta}-Cyclodextrin in Infants, Children, and Adolescents. Antimicrob. Agents Chemother. 51: 2668-2673 [Abstract] [Full Text]  
  • Mouton, J. W., van Peer, A., de Beule, K., Van Vliet, A., Donnelly, J. P., Soons, P. A. (2006). Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation. Antimicrob. Agents Chemother. 50: 4096-4102 [Abstract] [Full Text]  
  • Enoch, D. A., Ludlam, H. A., Brown, N. M. (2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol 55: 809-818 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 43: 3807-3810 [Abstract] [Full Text]  
  • Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., Courtney, R. (2004). Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects. Antimicrob. Agents Chemother. 48: 3543-3551 [Abstract] [Full Text]  
  • Pandya, N A, Atra, A A, Riley, U, Pinkerton, C R (2003). Role of itraconazole in haematology/oncology. Arch. Dis. Child. 88: 258-260 [Abstract] [Full Text]  
  • Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., Walsh, T. J. (2002). Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis. Antimicrob. Agents Chemother. 46: 2554-2563 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»